8 results about "FOXO1" patented technology

The present application relates to the application of delta-Viniferin in the preparation of drugs for preventing or treating metabolic cardiovascular diseases. Delta-Viniferin can inhibit the expression level of aging and inflammation related genes / proteins of vascular endothelial cells, reduce endothelial dysfunction, and clarify its anti-hypertensive effect. Delta-Viniferin can inhibit the expression level of vascular smooth muscle cell phenotype conversion related genes / proteins, improve the contraction function of vascular smooth muscle, and significantly alleviate the degradation of elastic fibers of the vascular wall and the rupture of the intima of the aortic wall in vivo, and clarify its effect on preventing and treating aortic dissection. Delta-Viniferin can inhibit the expression level of myocardial fibroblast fibrosis related genes / proteins, and clarify its anti-myocardial fibrosis effect. Delta-Viniferin can promote white adipose tissue browning by targeting the SIRT1-FOXO1 axis, increase energy consumption, and clarify its effect on resisting obesity. In summary, the compound delta-Viniferin has the effect of protecting various metabolic cardiovascular diseases, and can be used to prepare drugs for preventing and treating metabolic cardiovascular diseases.

In one aspect, methods of diagnosing a subject as having Alzheimer's disease and prognosing a subject as being at risk of progressing to Alzheimer's disease are provided. In some embodiments, the method comprises determining one or more of the level of expression of rhotekin 2 (RTKN2), the level of expression of microtubule-associated Ser / Thr kinase 4 (MAST4), the level of binding of forkhead box O1 (FOXO1) to the RTKN2 promoter, and the level of binding of amyloid precursor protein (APP) to the MAST4 promoter in a sample from the subject.

The invention relates to the technical field of biological medicines, in particular to application of HDAC7 as a target spot in diagnosis and treatment of rhabdomyosarcoma. The invention reveals for the first time that circular RNA (F-circP3F) sourced from an oncogenic fusion gene PAX3-FOXO1 is directly combined with and inhibits histone deacetylase HDAC7 to play a role through a novel mechanism, and HDAC7 can be used for early diagnosis, prognosis evaluation and curative effect monitoring of rhabdomyosarcoma as a core link of the regulation mechanism. And the method is a treatment intervention target with great potential.

The invention discloses an application of a polypeptide of a targeted NTRK3 gene in preparation of a medicine for inhibiting the growth of PAX3-FOXO1 fusion positive rhabdomyosarcoma. The invention provides the application of the NTRK3 protein as a drug target to preparation of the drug for resisting malignant proliferation of the PAX3-FOXO1 fusion positive rhabdomyosarcoma for the first time. Furthermore, by down-regulating the expression of the NTRK3 gene, the clone formation capability of the PAX3-FOXO1 fused positive rhabdomyosarcoma cells is remarkably inhibited. Therefore, the invention not only discloses the application of the NTRK3 gene, but also provides a new therapeutic target for the PAX3-FOXO1 fusion positive rhabdomyosarcoma. The invention provides possibility for preparing a novel medicine for treating the PAX3-FOXO1 fusion positive rhabdomyosarcoma and improving the prognosis condition of a patient.

The invention discloses application of an ENDOU inhibitor in preparation of a medicine for treating airway epithelium inflammation, and belongs to the field of biological medicine. The invention provides application of a reagent for detecting the expression level of ENDOU in preparation of a kit for diagnosing and / or detecting airway epithelium inflammation or bronchial asthma, and further provides application of an ENDOU inhibitor in preparation of a medicine for treating airway epithelium inflammation or bronchial asthma. The invention proves that ENDOU affects LPS-induced inflammatory response by regulating FOXO1 and IL-17A pathways, is a key molecule for regulating airway epithelial inflammation, is expected to become a therapeutic target for airway inflammation, provides a theoretical basis for research of related drug targets, also provides a new pathophysiology mechanism for occurrence of bronchial asthma, and has a broad application prospect. The composition can be used for preventing and treating bronchial asthma.

Compounds comprising a PAX3::FOXO1 fusion protein binding moiety, a bivalent linker, and an E3 ubiquitin ligase binding moiety. The compounds can be used to reduce PAX3::FOXO1 protein levels in a subject with fusion-positive rhabdomyosarcoma (FP-RMS), to ubiquitinate a PAX3::FOXO1 fusion protein in a cell, to treat FP-RMS in a subject in need thereof, and / or to treat a disease caused by the overexpression of PAX3::FOXO1 protein in a subject in need thereof.

The present application relates to the technical field of brain amyloid angiopathy drugs, and specifically discloses application of dendrobium alkaloid in preparation of a drug for preventing and treating brain amyloid angiopathy, wherein the drug for preventing and treating brain amyloid angiopathy comprises a FOXO1 expression upregulation / autophagy-lysosome activator, and the FOXO1 expression upregulation / autophagy-lysosome activator is dendrobium alkaloid. The drug of the present application increases clearance of Aβ while resisting inflammation and oxidation, reduces damage to cerebral blood vessels, and thus delays or improves cognitive impairment of patients with brain amyloid angiopathy; and through regulation of activation of vascular endothelial transcription factor FOXO1, toxicity of astrocytes is inhibited, and part of autophagy lysosome function is recovered.

Provided herein are compositions, systems, kits, and methods for treating a patient with cancer (e.g., Ewing's Sarcoma) by treating the patient with at least one of the following compositions: a) a composition comprising at least a portion of at least one fusion neoantigen selected from: EWSR1-FLi1, EWS-FEV, EWSR1-ERG, EWS-ATF, EWS-WT1, PAX7-FOXO1, CCNB3-BCOR, CIC-DVX, SS18-SSX2; b) a composition comprising a nucleic acid sequence encoding said at least a portion of said at least one fusion neoantigen; c) a composition comprising an antibody, or antigen-binding fragment, the specifically binds said at least a portion of said at least one fusion neoantigen; and / or d) a composition comprising a chimeric antigen receptor T-cell (CAR T cell) that expresses a chimeric antigen receptor that is specific for said at least a portion of said at least one fusion neoantigen.